1
|
Jiang L, Stoekenbroek RM, Zhang F, Wang Q, Yu W, Yuan H, Cai G, Chen Y, Li G, Yang Y, Zhang Y, Cheng X, Zhu H, Zhou H, Ye P, Yan S, Wang X, Wu W, Li R, Xie J, Jiao J, Cheng S, Niu W, Chen J, Yang S, Zhou Y, Kastelein JJ, Yang Y, Wang L. Homozygous Familial Hypercholesterolemia in China: Genetic and Clinical Characteristics from a Real-World, Multi-Center, Cohort Study. J Clin Lipidol 2022; 16:306-314. [DOI: 10.1016/j.jacl.2022.03.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 03/04/2022] [Accepted: 03/08/2022] [Indexed: 12/26/2022]
|
2
|
Zhang R, Xie J, Zhou J, Xu L, Pan Y, Qu Y, Li R, Chong M, Song L, Wen W, Wu Y, Li J, Wang L, Yang Y. Supravalvular Aortic Stenosis and the Risk of Premature Death Among Patients With Homozygous Familial Hypercholesterolemia. Am J Cardiol 2021; 145:58-63. [PMID: 33454344 DOI: 10.1016/j.amjcard.2020.12.080] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 12/22/2020] [Accepted: 12/29/2020] [Indexed: 12/13/2022]
Abstract
Patients with homozygous familial hypercholesterolemia (HoFH) have a high risk for premature death. Supravalvular aortic stenosis (SVAS) is a common and the feature lesion of the aortic root in HoFH. The relation between SVAS and the risk of premature death in patients with HoFH has not been fully investigated. The present study analysis included 97 HoFH patients with mean age of 14.7 (years) from the Genetic and Imaging of Familial Hypercholesterolemia in Han Nationality Study. During the median (±SD) follow-up 4.0 (±4.0) years, 40 (41.2%) participants had SVAS and 17 (17.5%) participants experienced death. The proportion of premature death in the non-SVAS and SVAS group was 7.0% and 32.5%, respectively. Compared with the non-SVAS group, SVAS group cumulative survival was lower in the HoFH (log-rank test, p <0.001). This result was further confirmed in the multivariable Cox regression models. After adjusting for age, sex, low density lipoprotein cholesterol (LDL_C)-year-score, lipid-lowering drugs, cardiovascular disease, and carotid artery plaque, SVAS was an independent risk factor of premature death in HoFH on the multivariate analysis (hazard ratio 4.45; 95% confidence interval, 1.10 to 18.12; p = 0.037). In conclusion, a significantly increased risk of premature death was observed in HoFH patients with SVAS. Our study emphasized the importance of careful and aggressive management in these patients when appropriate.
Collapse
|
3
|
Peng J, Wu X, Wang S, Zhang S, Wang X, Liu Z, Hong J, Ye P, Lin J. Familial hypercholesterolemia in China half a century: A review of published literature. ATHEROSCLEROSIS SUPP 2019; 36:12-18. [PMID: 30876527 DOI: 10.1016/j.atherosclerosissup.2019.01.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
AIMS To investigate the status of familial hypercholesterolemia (FH) research and the characteristics of patients with FH in China. METHODS Published papers in Chinese or English language from PubMed, SinoMed and CNKI databases from 1971 to March 2018 were searched using 'Familial hypercholesterolemia', 'Chinese' and 'Han' as keywords. A systematic review of studies on familial hypercholesterolemia was then conducted. RESULTS A total of 391 articles were found, in which 22% were in English and 78% were in Chinese; approximately 43% are case reports and 34% are genetic reports according to the study type; 52% discussed the status of the disease and 11% investigated the subclinical status according to the study content. Furthermore, 96% of the articles were published by tertiary hospitals and 46% were conducted by cardiologists. The first expert consensus was issued in February 2018. Of the 163 case reports published before 2018, 48.7% used the Chinese FH clinical diagnostic criteria and 34.4% did not clearly indicate the diagnostic criteria. The incidence rates of low-density lipoprotein receptor (LDLR) and apolipoprotein B (APOB) mutations were 82% and 9%, and proprotein convertase subtilisin/kexin type 9 (PCSK9) mutations were rare in Chinese patients with FH. However, the data on lipid-lowering treatment rates, compliance rates and cardiovascular events in FH remain insufficient. CONCLUSIONS Large-scale epidemiological investigation of FH has not been demonstrated, the recognition of FH remains rudimentary, and the guidelines are incomplete in China. The diagnosis and management of Chinese FH needs to be improved.
Collapse
Affiliation(s)
- Jie Peng
- Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases Beijing, 100029, China; Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
| | - Xue Wu
- Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases Beijing, 100029, China; Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
| | - Shilong Wang
- Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases Beijing, 100029, China; Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
| | - Shuang Zhang
- Department of Echo Cardiography, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
| | - Xumin Wang
- Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China.
| | - Zesen Liu
- Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases Beijing, 100029, China; Department of Echo Cardiography, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
| | - Jing Hong
- Department of Endocrinology and Metabolism, China-Japan Friendship Hospital, Beijing, 100029, China.
| | - Pucong Ye
- Department of Emergency Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
| | - Jie Lin
- Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases Beijing, 100029, China; Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
| |
Collapse
|